Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)

被引：0
作者：
Aleksandra Butrym
Ewa Lech-Maranda
Elżbieta Patkowska
Beata Kumiega
Maria Bieniaszewska
Andrzej Mital
Krzysztof Madry
Tigran Torosian
Ryszard Wichary
Justyna Rybka
Krzysztof Warzocha
Grzegorz Mazur
机构：
[1] Wroclaw Medical University,Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation
[2] Wroclaw Medical University,Department of Physiology
[3] Institute of Hematology and Transfusion Medicine,Department of Hematology
[4] Institute of Hematology and Transfusion Medicine,Centre of Postgraduate Medical Education, Warsaw
[5] Carpathian Oncology Centre,Department of Oncological Hematology
[6] Medical University of Gdansk,Department of Hematology and Transplantology
[7] Warsaw Medical University,Department of Hematology
[8] Silesian Medical University,Department of Hematology and Bone Marrow Transplantation
[9] Occupational Diseases and Hypertension,Department of Internal Medicine
[10] Wroclaw Medical University,Department of Hematology
[11] Institute of Hematology and Transfusion Medicine,undefined
来源：
BMC Cancer | / 15卷
关键词：
Myelodysplastic syndrome; del(5q); Lenalidomide; Transfusion independence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 83 条
[1]  
Butrym A(2012)Low risk myelodysplastic syndromes with del5q Acta Haematol Pol 43 331-5
[2]  
Dzietczenia J(2011)Biology and treatment of the 5q-syndrome Expert Rev Hematol 4 61-9
[3]  
Mazur G(2010)WHO-defined myelodysplastic syndrome with isolated del(5q) in 88 consequtive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations Leukemia 24 1283-9
[4]  
Padron E(2012)Blood consult: treating del(5q) myelodysplastic syndromes Blood 119 342-4
[5]  
Komrokji R(2012)Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases Leuk Res 36 656-7
[6]  
List AF(2011)Long-term remission after lenalidomide treatment in del(5q) syndrome - single center experience Acta Haematol Pol 42 325-30
[7]  
Patnaik MM(2011)MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. MDS-004 Lenalidomide del5q Study Group Blood 118 3765-76
[8]  
Lasho TL(2006)Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 1456-65
[9]  
Finke CM(2013)Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study Ann Hematol 92 25-32
[10]  
Gangat N(2013)Lenalidomide Performance in the real World. Patterns of use and effectiveness in a Medicare Population with myelodysplastic Syndromes Cancer 119 3870-388
123456789